TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07095075: An Open-label Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LUCAR-DKS1 in Subjects With Relapsed/Refractory Autoimmune Diseases (r/r AID)

Sponsor: Nanjing Legend Biotech Co. · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 36 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$4,035,120

Rescue Site Savings

+$2,674,440

Unlock Full NCT07095075 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07095075 Rescue Dossier →